Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand

Biochemical and Biophysical Research Communications
Bora OhInki Kim

Abstract

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic agent. However, tumor cells often develop resistance to TRAIL, limiting its therapeutic potential. To study the mechanism underlying TRAIL-resistance in breast cancer cells, we performed a high-throughput compound screen in MCF-7 cells. We identified daunorubicin as a potent sensitizer of TRAIL-induced apoptosis in MCF-7 cells. Daunorubicin in combination with subtoxic concentrations of recombinant human TRAIL induced massive apoptosis in MCF-7 cells. This combination was effective in TRAIL-resistant MDA-MB-231 and T47D breast cancer cells. By immunoblotting, we found that daunorubicin treatment induced loss of the anti-apoptotic protein, Mcl-1, in breast cancer cells. RNA interference experiments revealed that reduced expression of Mcl-1 sensitized MCF-7 cells to TRAIL. Together, these data suggest that Mcl-1 is a major contributor to TRAIL-resistance in breast cancer cells, and that reduction of Mcl-1 protein levels using DNA damaging agents is a promising approach for cancer therapy.

References

May 31, 1996·The Journal of Biological Chemistry·R M PittiA Ashkenazi
Apr 4, 1997·Science·G PanV M Dixit
Apr 21, 1999·Current Opinion in Cell Biology·A Ashkenazi, V M Dixit
Jun 6, 2000·Journal of Biomolecular Screening·J H ZhangK R Oldenburg
Apr 12, 2002·Oncogene·Simone FuldaKlaus-Michael Debatin
Mar 26, 2005·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Caroline M M Van GeelenSteven de Jong
Feb 16, 2006·The Journal of Biological Chemistry·Jie HanHannah Rabinowich
Feb 27, 2007·Oncogene·J M Adams, S Cory
Apr 18, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ronald KoschnyTom M Ganten
May 24, 2007·Apoptosis : an International Journal on Programmed Cell Death·Claudia Alexandra DumitruErich Gulbins
Jan 2, 2009·Cancer Treatment Reviews·Devalingam MahalingamAfshin Samali

❮ Previous
Next ❯

Citations

Aug 18, 2012·The Journal of Membrane Biology·Ammad Ahmad FarooqiShahzad Bhatti
Oct 17, 2012·Biochemical and Biophysical Research Communications·So Jung ParkDong-Hyung Cho
Sep 7, 2013·Biomolecules & Therapeutics·Seong Ho ParkDong-Hyung Cho
Feb 6, 2019·International Journal of Molecular Sciences·Sarah AlexandrouC Elizabeth Caldon
Jul 13, 2013·Molecular and Cellular Biochemistry·Sojung ParkInki Kim
Dec 10, 2016·Breast Cancer Research : BCR·Adelaide I J YoungSamantha R Oakes

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

International Journal of Cancer. Journal International Du Cancer
Baojun ChangMasayasu Inoue
Expert Opinion on Therapeutic Targets
Junaid Abdulghani, Wafik S El-Deiry
© 2021 Meta ULC. All rights reserved